Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases $40,000.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,500 shares of the stock in a transaction on Friday, October 2nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director directly owned 27,000 shares of the company’s stock, valued at approximately $432,000. This represents a 10.20% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dyne Therapeutics Stock Performance

DYN opened at $16.37 on Friday. The company has a 50 day simple moving average of $21.73 and a two-hundred day simple moving average of $20.50. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The firm has a market cap of $3.06 billion, a P/E ratio of -4.92 and a beta of 1.12. Dyne Therapeutics, Inc. has a 1-year low of $13.73 and a 1-year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Equities analysts forecast that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent analyst reports. Robert W. Baird dropped their price objective on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Wednesday, September 9th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the company from $17.00 to $10.00 in a research note on Wednesday, September 9th. Stifel Nicolaus set a $37.00 price target on Dyne Therapeutics in a report on Wednesday, September 30th. Morgan Stanley dropped their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.07.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics in the first quarter worth about $26,000. GAMMA Investing LLC grew its holdings in Dyne Therapeutics by 63.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,882 shares of the company’s stock valued at $30,000 after buying an additional 729 shares in the last quarter. Allworth Financial LP bought a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $62,000. Nykredit A S purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter worth approximately $113,000. Finally, Keating Financial Advisory Services Inc. purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter worth approximately $114,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.